FI2931265T6 - Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa - Google Patents
Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa Download PDFInfo
- Publication number
- FI2931265T6 FI2931265T6 FIEP13862780.7T FI13862780T FI2931265T6 FI 2931265 T6 FI2931265 T6 FI 2931265T6 FI 13862780 T FI13862780 T FI 13862780T FI 2931265 T6 FI2931265 T6 FI 2931265T6
- Authority
- FI
- Finland
- Prior art keywords
- axl
- variant polypeptide
- inhibitor
- seq
- soluble axl
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 5
- 230000002001 anti-metastasis Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 2
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102220012991 rs111033344 Human genes 0.000 claims 2
- 102220044222 rs587781255 Human genes 0.000 claims 2
- 102220258833 rs764229797 Human genes 0.000 claims 2
- 102220098139 rs878852992 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102200053909 rs2638525 Human genes 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737276P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/074786 WO2014093690A1 (en) | 2012-12-14 | 2013-12-12 | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI2931265T6 true FI2931265T6 (fi) | 2023-05-23 |
Family
ID=50934967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP13862780.7T FI2931265T6 (fi) | 2012-12-14 | 2013-12-12 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9822347B2 (OSRAM) |
| EP (2) | EP2931265B3 (OSRAM) |
| JP (2) | JP6345690B2 (OSRAM) |
| AU (3) | AU2013359179B2 (OSRAM) |
| CA (1) | CA2894539C (OSRAM) |
| DK (2) | DK2931265T6 (OSRAM) |
| ES (2) | ES2862335T3 (OSRAM) |
| FI (1) | FI2931265T6 (OSRAM) |
| NO (1) | NO3049208T3 (OSRAM) |
| PT (2) | PT2931265T (OSRAM) |
| WO (1) | WO2014093690A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011207381B2 (en) * | 2010-01-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| ES2862335T3 (es) | 2012-12-14 | 2021-10-07 | Univ Leland Stanford Junior | Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica |
| CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| CA2971406A1 (en) * | 2014-12-18 | 2016-06-23 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
| US20200289613A1 (en) * | 2017-11-04 | 2020-09-17 | Aravive Biologics, Inc. | Methods of treating metastatic cancers using axl decoy receptors |
| WO2023039254A1 (en) * | 2021-09-11 | 2023-03-16 | Aravive Inc | Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5538861A (en) * | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US20030166110A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| WO2004108748A2 (en) | 2002-09-24 | 2004-12-16 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
| JP2006524496A (ja) | 2003-04-18 | 2006-11-02 | ノバルティス アクチエンゲゼルシャフト | 骨関節炎の診断および処置のためのチロシンキナーゼを標的化する方法および組成物 |
| JP2005278631A (ja) | 2004-03-04 | 2005-10-13 | National Institute Of Advanced Industrial & Technology | Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法 |
| EP1825005B1 (en) | 2004-11-24 | 2015-07-15 | The Regents of the University of Colorado, a body corporate | Mer diagnostic and therapeutic agents |
| WO2006118308A1 (ja) | 2005-05-02 | 2006-11-09 | Toray Industries, Inc. | 食道ガン及び食道ガン転移診断のための組成物及び方法 |
| US8168415B2 (en) * | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
| WO2008128072A2 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
| EP2170395A1 (en) | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| CA2747678A1 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| KR20120035145A (ko) * | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| AU2011207381B2 (en) * | 2010-01-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| US10844106B2 (en) | 2010-11-08 | 2020-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| US20150315552A1 (en) | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
| ES2862335T3 (es) * | 2012-12-14 | 2021-10-07 | Univ Leland Stanford Junior | Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica |
| WO2015030849A1 (en) * | 2013-08-30 | 2015-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | High-affinity binding to gas6 |
| CA2909669C (en) * | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| CA2971406A1 (en) * | 2014-12-18 | 2016-06-23 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
-
2013
- 2013-12-12 ES ES17196662T patent/ES2862335T3/es active Active
- 2013-12-12 US US14/650,854 patent/US9822347B2/en not_active Expired - Fee Related
- 2013-12-12 EP EP13862780.7A patent/EP2931265B3/en active Active
- 2013-12-12 DK DK13862780.7T patent/DK2931265T6/da active
- 2013-12-12 EP EP17196662.5A patent/EP3326622B1/en active Active
- 2013-12-12 FI FIEP13862780.7T patent/FI2931265T6/fi active
- 2013-12-12 WO PCT/US2013/074786 patent/WO2014093690A1/en not_active Ceased
- 2013-12-12 CA CA2894539A patent/CA2894539C/en active Active
- 2013-12-12 ES ES13862780T patent/ES2665323T7/es active Active
- 2013-12-12 AU AU2013359179A patent/AU2013359179B2/en not_active Ceased
- 2013-12-12 JP JP2015547567A patent/JP6345690B2/ja active Active
- 2013-12-12 PT PT138627807T patent/PT2931265T/pt unknown
- 2013-12-12 PT PT171966625T patent/PT3326622T/pt unknown
- 2013-12-12 DK DK17196662.5T patent/DK3326622T3/da active
-
2014
- 2014-06-30 NO NO14741534A patent/NO3049208T3/no unknown
-
2017
- 2017-10-13 US US15/783,850 patent/US11136563B2/en not_active Expired - Fee Related
- 2017-12-06 AU AU2017272193A patent/AU2017272193A1/en not_active Abandoned
-
2018
- 2018-05-23 JP JP2018098435A patent/JP6832887B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-02 AU AU2019210662A patent/AU2019210662B2/en not_active Ceased
-
2021
- 2021-09-02 US US17/465,203 patent/US20220220458A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6345690B2 (ja) | 2018-06-20 |
| ES2665323T3 (es) | 2018-04-25 |
| ES2665323T7 (es) | 2023-06-15 |
| CA2894539A1 (en) | 2014-06-19 |
| AU2017272193A1 (en) | 2017-12-21 |
| EP2931265B1 (en) | 2018-01-31 |
| US11136563B2 (en) | 2021-10-05 |
| US9822347B2 (en) | 2017-11-21 |
| EP2931265A1 (en) | 2015-10-21 |
| DK2931265T6 (da) | 2023-05-01 |
| EP3326622B1 (en) | 2021-01-20 |
| HK1256071A1 (en) | 2019-09-13 |
| US20220220458A1 (en) | 2022-07-14 |
| DK3326622T3 (da) | 2021-04-06 |
| DK2931265T3 (en) | 2018-04-16 |
| AU2019210662B2 (en) | 2021-07-01 |
| EP2931265A4 (en) | 2016-08-31 |
| US20150315553A1 (en) | 2015-11-05 |
| AU2013359179B2 (en) | 2017-10-05 |
| JP2016510309A (ja) | 2016-04-07 |
| PT2931265T (pt) | 2018-04-16 |
| WO2014093690A1 (en) | 2014-06-19 |
| PT3326622T (pt) | 2021-04-07 |
| EP2931265B3 (en) | 2023-04-05 |
| AU2013359179A1 (en) | 2015-07-02 |
| US20180030422A1 (en) | 2018-02-01 |
| JP2018154641A (ja) | 2018-10-04 |
| ES2862335T3 (es) | 2021-10-07 |
| NO3049208T3 (OSRAM) | 2018-04-14 |
| JP6832887B2 (ja) | 2021-02-24 |
| AU2019210662A1 (en) | 2019-08-22 |
| EP3326622A1 (en) | 2018-05-30 |
| CA2894539C (en) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI2931265T6 (fi) | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| JP2012082206A5 (OSRAM) | ||
| RU2011141522A (ru) | Антиангиогенные слитые белки | |
| IN2012DN03368A (OSRAM) | ||
| MX2014000210A (es) | Peptidos procoagulantes y sus derivados, y usos para estos. | |
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| NZ624533A (en) | Novel immunotherapy against several tumors including neuronal and brain tumors | |
| JP2017160222A5 (OSRAM) | ||
| AR065289A1 (es) | Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple | |
| PH12014501083A1 (en) | Anticancer fusion protein | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2015524403A5 (OSRAM) | ||
| WO2016004906A3 (zh) | 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用 | |
| MX352796B (es) | Proteina de fusion anticancerigena. | |
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| JP2012529293A5 (OSRAM) | ||
| NZ610620A (en) | Inhibitors of apoptosis and uses thereof | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда |